1. Home
  2. MIRM vs AROC Comparison

MIRM vs AROC Comparison

Compare MIRM & AROC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$91.35

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Logo Archrock Inc.

AROC

Archrock Inc.

HOLD

Current Price

$26.87

Market Cap

4.5B

Sector

Energy

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRM
AROC
Founded
2018
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Oil & Gas Production
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.5B
IPO Year
2019
1997

Fundamental Metrics

Financial Performance
Metric
MIRM
AROC
Price
$91.35
$26.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
5
Target Price
$97.55
$32.40
AVG Volume (30 Days)
836.6K
1.2M
Earning Date
02-25-2026
02-23-2026
Dividend Yield
N/A
3.12%
EPS Growth
N/A
65.71
EPS
N/A
1.50
Revenue
$471,794,000.00
$1,439,161,000.00
Revenue This Year
$54.25
$31.39
Revenue Next Year
$21.09
$6.64
P/E Ratio
N/A
$17.90
Revenue Growth
53.66
31.94
52 Week Low
$36.88
$20.12
52 Week High
$93.70
$30.44

Technical Indicators

Market Signals
Indicator
MIRM
AROC
Relative Strength Index (RSI) 71.95 62.45
Support Level $85.98 $25.56
Resistance Level $93.70 $26.52
Average True Range (ATR) 3.83 0.71
MACD 0.95 0.03
Stochastic Oscillator 87.40 75.58

Price Performance

Historical Comparison
MIRM
AROC

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About AROC Archrock Inc.

Archrock Inc is an energy infrastructure company with a focus on midstream natural gas compression and a commitment to helping customers produce, compress, and transport natural gas. It has two business segments, Contract Operations, and Aftermarket Services. Under the umbrella of contract operations services, the company provides operations to meet customers' natural gas compression needs. Services include designing, owning, installing, operating, and maintaining equipment. Aftermarket Services business provides a full range of services to support the compression needs of customers who own compression equipment, including operations, maintenance, overhaul, and reconfiguration services, and sales of parts and components. It generates maximum revenue from the Contract Operations segment.

Share on Social Networks: